A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Alkermes owns proprietary technology for momentarily relaxing the Blood-Brain barrier which would allow medication to be administered directly to the brain for the treatment of CNS conditions.
Furthermore, ALZA has taken a 7% interest in ALKS prior to be acquired by JNJ. Therefore, not only is JNJ partnered with ALKS for Risperdal Consta, but it has a 7% stake in the company.
Add to that their other partnerships which employ the ALKS AIR technology for inhalable medications (Insulin?) and their subcutaneous time-release technology (Medisorb) which reduces the number of times an individual must inject medications that are required over a prolonged period of time , and-----I believe we have a potential Blockbuster!